Abstracts tagged "plasma cells"

Abstract Number: 2825 • 2018 ACR/ARHP Annual Meeting
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
Ana Martínez^1,2, Chamaida Plasencia^2,3, Victoria Navarro-Compán², Borja Hernández-Breijo², Dora Pascual-Salcedo², Pilar Nozal⁴, Cristina Diego⁴, Irene Monjo^2,3, Laura Nuño^3,5 and Alejandro Balsa^2,6, ¹Immunology. La Paz University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ³Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴La Paz University Hospital, Immunology, Madrid, Spain, ⁵Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Rituximab (Rtx) induces transient depletion of B cells. Previous data showed that Rtx is particularly effective on autoimmune diseases in which auto-antibodies (auto-Ab) are…
Abstract Number: 1085 • 2016 ACR/ARHP Annual Meeting
The Anti-CD38 Monoclonal Antibody TAK-079 Depletes Antibody Secreting Cells from Normal and SLE Patients
Xiaoqian Wang¹, Martin Dahl², Doan Nguyen³, Scott Jenks¹, Kevin Cashman¹, F. Eun-Hyung Lee⁴, Lachy McLean⁵ and Ignacio Sanz⁶, ¹Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ²Tekada Pharmaceuticals, San Diego, CA, ³Emory University School of Medicine, Atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA, ⁵Takeda Global Research & Development Center, Inc, San Diego, CA, ⁶Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by expanded antibody secreting cells (ASCs) and the production of a variety of autoantibodies. Depletion of B cells…
Abstract Number: 3216 • 2016 ACR/ARHP Annual Meeting
Integrated High-Dimensional Analyses Reveal a Pathologically Expanded ‘Peripheral’ B Cell-Helper T Cell Population in Rheumatoid Arthritis
Deepak Rao¹, Michael Gurish², Kamil Slowikowski³, Chamith Fonseka², Jennifer Marshall⁴, Yanyan Liu⁵, Laura T. Donlin⁶, Lauren Henderson⁷, Fumitaka Mizoguchi⁸, Nikola Teslovich⁹, Michael Weinblatt¹⁰, Elena Massarotti¹⁰, Jonathan Coblyn¹¹, Simon M. Helfgott¹⁰, Yvonne C. Lee¹², Derrick J. Todd¹⁰, Vivian P. Bykerk¹³, Susan M. Goodman¹⁴, Alessandra B. Pernis¹⁵, Lionel Ivashkiv¹⁴, Elizabeth W. Karlson¹⁰, Peter Nigrovic⁹, Andrew Filer¹⁶, Christopher Buckley¹⁷, James Lederer¹⁸, Soumya Raychaudhuri¹⁹ and Michael Brenner¹, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Divisions of Rheumatology and Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁷Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁸Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Brigham and Women's Hospital and Harvard Medical School, Cambridge, MA, ¹⁰Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹³Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁴Medicine, Hospital for Special Surgery, New York, NY, ¹⁵David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Rheumatology, University of Birmingham, Birmingham, United Kingdom, ¹⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Determining the pathologic functions of T cells that infiltrate target tissues remains a central challenge in autoimmune diseases. In rheumatoid arthritis (RA), the formation…
Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Marieke E. Doorenspleet¹, Paul L. Klarenbeek¹, Maartje J. Boumans¹, Rogier M. Thurlings², Rebecca E. Esveldt¹, Barbera D. van Schaik³, Antoine H. van Kampen³, Danielle M. Gerlag⁴, Frank Baas⁵, Paul-Peter Tak¹, Robert M. Plenge⁶ and Niek de Vries¹, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Bioinformatics, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Genome Analysis, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…
Abstract Number: 2678 • 2012 ACR/ARHP Annual Meeting
Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis
Teresa Owen¹, Wensheng Wang¹, Dilara McCauley², Laura Strojny¹, Jennifer Hossler¹, Javier Rangel-Moreno³, Michael Kauffman², Sharon Shacham⁴ and Jennifer H. Anolik⁵, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Karyopharm, Therapeutics Inc., Natick, MA, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴Karyopharm Therapeutics Inc., Natick, MA, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Most therapies currently used to treat systemic lupus erythematosus (SLE) and B cell targeted therapies under development do not effectively target plasma cells and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].